ILUSTRASI. Research associate Sachi Johnson works at Sorrento Therapeutics where efforts are underway to develop an antibody, STI-1499, to help in prevention of the coronavirus disease (COVID-19) in San Diego, California, U.S., May 22, 2020. REUTERS/Bing Guan
Source: CNBC | Editor: I knew Laoli
KONTAN.CO.ID – LONDON. The development of the corona virus vaccine carried out by the University of Oxford in England showed positive immunity. In the initial testing phase, this vaccine shows a strong immune response, according to data released on Monday (7/20) in the medical journal The Lancet.
Oxford researchers who partnered with pharmaceutical giant AstraZeneca released that their experimental vaccine ChAdOx1 nCov-19, changed the genetic material of the corona virus with modified adenoviruses, which are known to cause infection in chimpanzees. The first phase of the trial involved more than 1,000 participants.
The director of the Jenner Institute Oxford University, Professor Adrian Hill, told CNBC on Monday that the vaccine provides a strong immune response. This means that the vaccine can protect us against viruses, although so far it cannot be guaranteed.
But it will conduct more trials on humans in the United States (US) in the next few weeks.
“We use a single dose and two vaccine doses,” he told “Worldwide Exchange.”
“It seems that both of them provided useful immune responses even though after two doses we saw a stronger immune response. And to continue to follow these people and start trials elsewhere. Hopefully in the US in the next few weeks, “Hill said.
The vaccine for Oxford is one of at least 100 candidate vaccines developed worldwide for Covid-19, which has infected more than 14 million people worldwide and killed at least 606,206 people, according to data compiled by Johns Hopkins University.
Also Read: The final clinical trial in Indonesia, this is the Sinovac corona vaccine
Last week, the biotech company Moderna released promising data on a potential corona virus vaccine trial, saying it produced a strong immune response. The trial included 45 healthy participants and was run by the National Institutes of Health.
